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Abstract Glutamic acid decarboxylase (GAD) is a major
inhibitory neurotransmitter in the brain, which catalyses the
reaction of L-glutamate to γ-aminobutyric acid. There are
two isoforms of GAD, a 65-kDa form and a 67-kDa form,
which are encoded by two different genes. As previous
studies suggested a role for GAD67 splice variants during
fetal pancreas development, we have investigated the
mRNA expression of GAD67 and GAD67 splice variants
in a series of 14 human fetal pancreases between 14 weeks
gestation and term and in adult control pancreases by RT-
PCR. In this study, we demonstrate mRNA expression of
GAD67 and four GAD67 splice variants, including GAD25,
in human fetal and adult specimens. Some of the splice
variants, including various proportions of exon 7 or a new
exon between exons 6 and 7, have not been described
before in the human pancreas. We speculate that the
expression of these GAD67 splice variants might be related




Two forms of glutamic acid decarboxylase (GAD) occur in
mammalian tissues: a 65 kDa form (GAD65) and a 67-kDa
form (GAD67). GAD65 and GAD67 are enzymes that
catalyze the reaction of L-glutamate to γ-aminobutyric acid,
a major inhibitory neurotransmitter in the central nervous
system. The two GAD isoforms are highly homologous but
are encoded by separate genes [1]. GAD65 is localized on
chromosome 10, and GAD67 on chromosome 2 [2].
Alternative splicing of the GAD67 gene can result in two
additional isoforms of the protein [3, 4].
In humans, autoreactivity against GAD is often found in
type 1 diabetes mellitus. Some 10 to 30% of the newly
diagnosed patients have GAD67 antibodies, and up to 80%
have GAD65 antibodies. Because the prevalence of
GAD67 autoreactivity is less than GAD65, and is usually
detected in patients with GAD65 antibodies, the GAD67
antibodies are assumed to play a less prominent role in the
pathogenesis of β-cell destruction [3]. However, there are
studies where GAD67 reactivity was found in patients
without reactivity against GAD65 [5–7].
GAD65 and GAD67 are both highly expressed in the
brain, but the two forms appear to be differentially
expressed in pancreatic islets. In human islets, GAD65 is
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histochemistry, in situ hybridization, immunoprecipitation,
or Western blotting [3, 8–10]. In one study, limited GAD67
expression was demonstrated in human islets by RNase
protection analysis [11]. In contrast, rat islets express both
forms, whereas mouse islets express predominantly GAD67
[4, 8, 10, 12, 13].
In addition to the native form of GAD67, of which exon
7 is spliced out of the mRNA, other forms of alternative
splicing of the GAD67 gene have been described in the
rodent brain. This alternative splicing resulted in two
additional GAD transcripts in which either the first 80 or
the first 86 bp of exon 7 were inserted into the full length
GAD67 message, respectively [4, 14]. Transcripts with the
80-bp insertion result in two overlapping open reading
frames, encoding an enzymatically inactive 25-kDa protein
(GAD25) and an enzymatically active 44-kDa protein
(GAD44). A second stop codon at the end of the 86-bp
insertion abolishes the translation of GAD44 (Fig. 1A). This
alternative splicing was only observed in embryonic and
fetal mice, but not in adult animals [4, 14, 15], leading to
the conclusion that this alternative splice variant could have
a developmental function. Alternative splicing of the
GAD67 gene has also been demonstrated in cells of adult
human pancreatic islets. Exon 7 was inserted after exon 6 of
GAD67, resulting in a shorter transcript of GAD67 mRNA,
encoding GAD25 [3].
The potential role of GAD in pancreas development [4,
16] and the lack of knowledge of the normal expression of
different GAD isoforms during normal fetal pancreas
development led us to investigate GAD expression at the
mRNA level in a series of human fetal pancreas specimens
of 14 weeks gestation until term. In this paper, we
demonstrate GAD67 and GAD67 splice variants, including
GAD25 mRNA expression by RT-PCR, between 14 weeks
gestation and term and in the adult pancreas.
Materials and Methods
Tissue Specimens
Human fetal (n=14) and adult (n=4) pancreatic specimens
were retrieved from the Erasmus MC Tissue Bank,
Department of Pathology, Rotterdam, The Netherlands,
following approval of the experimental design and proto-
cols by the Medical Ethical Committee. The fetuses had
died of causes not related to the pancreas. Autopsy was
performed within 24 h after death. The adult pancreatic
tissue was obtained from normal tissue in pancreatic
Fig. 1 A Schematic representa-
tion of exon 6 to exon 10 of
GAD67, including the localiza-
tion of the primers used for the
RT reaction (GAD67.Ar) and
PCR (GAD25.1f, GAD25.1r,
GAD67.1f, and GAD67.1r). In
the adult form, exon 7 is spliced
out of the mRNA, but in em-
bryonic mouse brain, a part of
exon 7 is spliced out in two
different ways. Either the first
80 bp (I-80) or the first 86 bp
(I-86) is retained in the mRNA,
and because an overlapping
translation stop–start sequence
occurs after 34 nucleotides in
exon 7, the I-80 and I-86 inserts
result in two “open reading
frames” (ORFs) and one ORF,
respectively, as displayed in
subpanel (B). B Overview of
alternative mRNA splice var-
iants, including the predicted
ORFs; ORF1 encodes GAD67,
ORF2 encodes GAD25, whereas
ORF3 encodes GAD44. The
additional 6 bp in the I-86
message contains an in-frame
stop codon which abolishes the
translation of GAD44
32 Endocr Pathol (2007) 18:31–36resection specimens. Histological analyses confirmed the
presence of normal tissue in these adult pancreas samples.
Fourteen snap-frozen pancreatic samples between
14 weeks gestation and term (gestational ages: 14, 16, 18,
19, 21, 26, 27, 29, 32 (n=2), 33, 36, and 40 (n=2) weeks,
respectively) and four adult snap-frozen pancreatic samples
were stored in liquid nitrogen and were used to isolate
RNA. Paraffin samples were fixed by immersion in 4%
buffered formaldehyde and embedded in paraffin according
to the standard procedures.
RNA Isolation
Total RNA was extracted using Trizol reagent (Life
Technologies, Rockville, MD, USA) following the manu-
facturer’s instructions. After RNA isolation, the quality of
5 μg RNA was checked with an MOPS gel (0.2 M 3-N-
morpholinepropanesufonic acid, 0.05 M sodium acetate,
and 0.01 M Na2EDTA).
cDNA Synthesis and PCR Amplification
One microgram of total RNA from 18 pancreases was
reverse-transcribed with a mix of specific reverse primers
for GAD67 (5′-AGTGACTCTGTTCTGAGGTG-3′),
POLR2A (5′-TTGTTAGAGTCCACAAGCAG-3′), and
oligo-dT (T12). cDNA synthesis was performed in a final
volume of 20 μl containing 50 mM Tris–HCl (pH 8.3),
75 mM KCl, 3 mM MgCl2, 10 mM DTT, 3 pM specific
primer mix, 1 mM dNTPs, 200 U Moloney murine
leukemia virus (M-MLV) reverse transcriptase (Invitrogen,
San Diego, CA, USA), and 30 U RNase inhibitor
(Promega, Madison, WI, USA). The RT mix was incubated
for 1 h at 37°C. Polymerase chain reaction was performed
with 1 μl cDNA in a final volume of 15 μl containing
1.5 mM MgCl2; 10 mM Tris–HCl; 50 mM KCl; 0.02 mM
dATP; 0.2 mM dGTP, dTTP, and dCTP; 0.8 μCi α
32P-
dATP (Amersham, Buckinghamshire, United Kingdom),
15 pmol of each forward and reverse primer for GAD67 and
POLR2A (Table 1), and 1 U Taq polymerase (Promega,
Madison, WI, USA). PCR was performed for 35 cycles at
95°C for 30 s, 58°C for 45 s, and 1 min at 72°C, followed
by 1 cycle at 72°C for 10 min. PCR products were run on a
denaturing 6% polyacrylamide gel (Fluka, Neu-Ulm,
Germany). After electrophoresis, the gel was dried and
exposed to an x-ray film. Negative controls for the RT
reaction were performed by omission of either M-MLV
reverse transcriptase or RNA, and for the PCR by omission
of cDNA.
DNA Sequencing
To confirm that the additional bands represented both
splicing forms, two 50 μl PCRs were performed with two
cDNA samples, respectively, at 14 and 19 weeks. Polymer-
ase chain reaction was performed under the identical
conditions as the previous PCR except that this mix
contained 0.2 mM dNTPs instead of 0.02 mM dATPs and
0.8 μCi α
32P-dATP. The PCR products were run on a 2%
agarose gel, and the additional bands were excised out of
the gel and purified using a QIAquick Gel Extraction Kit
(Westburg, Leusden, The Netherlands) according to the
manufacturer’s instructions. The purified PCR products




The housekeeping gene POLR2A was used as a positive
control for the RT reaction and showed positive results for
all samples (Fig. 2A). Using the GAD67 primers, four
distinct PCR products per sample were observed. In all
samples, a 200-bp amplified product was present, which
represents the adult GAD67 isoform, without insertion of
exon 7. The 280-bp product and the 286-bp product were
highly reproducible and detected in most fetal and all adult
samples (Fig. 2C). Three fetal pancreatic samples showed
only the 286-bp additional band. An additional PCR
product of about 330-bp appeared reproducibly in the
majority of samples. This product was sequenced, as well
as the 280-bp and the 286-bp PCR products (see below). To
detect the GAD25 mRNA, we performed PCR with specific
primers for GAD25, i.e., a forward primer in exon 6 and a
reverse primer in the last part of exon 7 (Fig. 1). The results
show an expression of this GAD25 form in all fetal and
adult pancreas specimens (Fig. 2C). In general, there
appeared to be no differences in expression levels by RT-
Table 1 Primers used for PCR
Specificity Forward (5’-3’) Reverse (5’-3’) Expected product size
GAD67 gagaatggctgacatcaacg gaagtacttgtagcgagcag 200 bp
GAD25 tttcaaccagctctcca tgcagttaccatcacctctg 189 bp
POLR2A cggatgaactgaagcgaatg ttgttagagtccacaagcag 188 bp
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samples for all of the primer combinations used.
Sequence Analysis
Sequence analysis with specific forward and reverse
primers revealed that the two additional PCR products of
280 and 286 bp consisted of the adult form with an
insertion of either the first 80 or 86 bp of exon 7. The
additional product of 330 bp (Fig. 3), consisting of exons 6
to 9, with an insertion of 68 bp between exons 6 and 7
(Fig. 4), appeared to be a new splice product. This new
exon wasflankedbyauthenticsplicejunctions:5′-AG/GT-3′.
The additional sequence was homologous to a part of intron
6 of the human GAD67 gene (51.128–51.195 of Gen-
Bank™ accession number AC007405). The first 213 amino
acids of the predicted protein are homologous to GAD25,
followed by another 26 amino acids. The predicted
molecular weight would approximately be 29.3 kDa.
Discussion
The potential role for GAD in pancreas development and
the lack of knowledge about the distribution of the isoforms
and splice variants of GAD led us to investigate GAD67 and
GAD25 expression in the human fetal pancreas. We
performed RT-PCR, on human fetal and adult pancreases,
and found mRNA expression of GAD67 and GAD25 from
14 weeks gestation onward until term, as well as in the
adult pancreas specimens. Apart from the adult form of
GAD67, the RT-PCR experiments revealed three additional
splice variants, which have not been described previously
in the human pancreas.
Our study revealed GAD67 mRNA expression in all
fetal and adult pancreases. Whereas GAD67 expression at
the mRNA and protein level is well established in the
mouse pancreas, only a few studies, using RNA protection
assay analysis and RT-PCR, have demonstrated GAD67
mRNA expression in the human pancreas [11, 17]. In
contrast, GAD67 was never detected in the human pancreas
at the protein level, although some studies found GAD67
autoantibodies in type 1 diabetes mellitus patients, in the
absence of GAD65 autoantibodies [5–7]. An explanation
for the negative findings of previous studies could be that
the GAD67 protein has already degraded because the half-
life of the GAD67 protein is less than 4 h [18].
According to the literature, alternative splicing of the
GAD67 gene results in at least four mRNA products [3, 4].
Fig. 3 Four distinct RT-PCR
products appear when GAD67
primers are used in this human
fetal pancreas of 16 weeks of
gestation. In lane 1, the native
GAD67 PCR product of 200 bp
is seen. Lane 2 represents the
PCR products of the I-80 and
I-86 splice variants, whereas
lane 3 shows the newly found
PCR product of 330 bp
Fig. 2 A–C Results of RT-PCR
experiments of seven represen-
tative samples, with primers
against POLR2A (A), GAD67
(B), and GAD25 (C). The
arrows indicate the sizes of the
PCR products, which are 188 bp
for POLR2A (A); 200, 280, and
286 bp for GAD67, respectively
(B); and 189 bp for GAD25 (C)
34 Endocr Pathol (2007) 18:31–36In our study, we demonstrate four GAD67 mRNA isoforms
in the human fetal and adult pancreas samples. The first
discovered transcript was an mRNA product, which lacks
exon 7 and encodes for the native 67-kDa protein (GAD67)
(see the “Results” section). A second transcript comprised
the first seven exons of the GAD67 gene, encoding a 25-
kDa protein (GAD25). This variant was previously reported
in human nonneural tissues by Chessler et al. [19]. A third
and fourth transcript contained the first 80 or 86 bp of exon
7. So far, these mRNA variants have only been described in
embryonic mouse brain [3, 4]. In contrast to the mouse
brain, where the GAD67 mRNA splice variants seem to
have a developmentally regulated expression pattern [4],
we did not see an increase of the 80-bp splice form, nor did
we detect a decrease of the 86-bp during gestation,
compared to each other in the same sample. In addition,
all different mRNA isoforms described above were detected
in most human fetal pancreases from 14 weeks of gestation
until term even in the adult pancreases. It should be noted,
though, that these experiments were not set up to yield
quantitative data and therefore must be interpreted with
caution.
The additional RT-PCR product of 330 bp represents a
heretofore undescribed splice variant of GAD67,w i t ha n
insertion of an unknown exon before the I-86 insert. The
predicted protein would consist of 213 amino acids, of
which the first part consists of the same amino acids as
GAD25, followed by another 26 amino acids, and would
have a molecular weight of approximately 29 kDa. Szabo
et al. [4] observed two isoforms of approximately 31 and
32 kDa in embryonic mouse brain by Western blot. These
products were assumed to be the result of posttranslational
modifications. The predicted protein of our newly found
splice variant might actually represent one or both of the
proteins found by Szabo et al. [4].
In summary, we found GAD67 mRNA expression during
the entire gestational period investigated. In addition,
GAD67 splice variants were present in both fetal and adult
pancreases. We also found a heretofore undescribed GAD67
mRNA splice variant, which is also found in the fetal and
adult pancreases. These results suggest that GAD67 and its
splice variants might play a role in the developing human
fetal pancreas and in the maintenance of the human adult
pancreas.
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